Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its holdings in Krystal Biotech, Inc. by 45.0%, with a current value of $2.30 million post the sale of over 10,000 shares.
• Several institutional investors increased their stakes in Krystal Biotech, including Fifth Third Bancorp, which boosted its holdings by 159.1%.
• Research analysts have a consensus rating of "Buy" for Krystal Biotech, with an average price target of $211.33, indicating strong optimism about the stock's future performance.

Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 45.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,753 shares of the company's stock after selling 10,444 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH's holdings in Krystal Biotech were worth $2,299,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Fifth Third Bancorp increased its position in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Krystal Biotech in the 4th quarter valued at approximately $95,000. GAMMA Investing LLC increased its stake in shares of Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after purchasing an additional 432 shares during the last quarter. Covestor Ltd boosted its stake in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Krystal Biotech in the 1st quarter valued at $223,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the transaction, the insider owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 49,800 shares of company stock valued at $7,487,943 over the last 90 days. 13.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KRYS. Bank of America dropped their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Chardan Capital restated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Friday, July 25th. Citigroup restated a "neutral" rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. Guggenheim reduced their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research report on Friday, July 25th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $211.33.

Krystal Biotech Trading Up 0.7%

Shares of KRYS stock traded up $1.14 during trading hours on Wednesday, reaching $153.22. 304,959 shares of the company's stock were exchanged, compared to its average volume of 264,576. The company has a market cap of $4.43 billion, a price-to-earnings ratio of 36.83 and a beta of 0.67. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $212.06. The stock's 50 day moving average is $139.09 and its 200-day moving average is $155.65.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. Equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).